1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 1,267 results.

Thumbnail for Trends and Disparities in Mortality due to Multiple Myeloma and Malignant Plasma Cell Neoplasms Coexisting with Malignant Neoplasms: A 26-Year CDC Wonder Analysis From 1999 - 2024

MM - 287

Trends and Disparities in Mortality due to Multiple Myeloma and Malignant Plasma Cell Neoplasms Coexisting with Malignant Neoplasms: A 26-Year CDC Wonder Analysis From 1999 - 2024

Atif Hussain Sarwar

Poster Presenter: Atif Hussain Sarwar

Thumbnail for Incidence of Parkinsonism and Non-ICANS Neurotoxicity with BCMA-Targeting Bispecific Antibodies vs CAR T-Cell Therapy in Multiple Myeloma: A Systematic Review and Meta-Analysis

MM - 307

Incidence of Parkinsonism and Non-ICANS Neurotoxicity with BCMA-Targeting Bispecific Antibodies vs CAR T-Cell Therapy in Multiple Myeloma: A Systematic Review and Meta-Analysis

Elias Tayar

Poster Presenter: Elias Tayar

Thumbnail for Triplet vs Quadruplet Induction Regimens in Transplant-Eligible and Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Trials

MM - 315

Triplet vs Quadruplet Induction Regimens in Transplant-Eligible and Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Trials

Elias Tayar

Poster Presenter: Elias Tayar

Thumbnail for New IMS/IMWG Consensus Genomic Staging (CGS) Risk Criteria by Next-Generation Sequencing (NGS): Analysis of Daratumumab Benefit in Both High- and Standard-Risk Patients in the PERSEUS/EMN017 Study

MM - 326

New IMS/IMWG Consensus Genomic Staging (CGS) Risk Criteria by Next-Generation Sequencing (NGS): Analysis of Daratumumab Benefit in Both High- and Standard-Risk Patients in the PERSEUS/EMN017 Study

Meletios A Dimopoulos

Poster Presenter: Meletios A Dimopoulos

Video

Thumbnail for Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM): Final Analysis of Transplant-Ineligible (TIE) Patients in the Phase 3 CEPHEUS Study

MM - 338

Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM): Final Analysis of Transplant-Ineligible (TIE) Patients in the Phase 3 CEPHEUS Study

Saad Z Usmani

Poster Presenter: Saad Z Usmani

Video

$Thumbnail for Teclistamab Plus Daratumumab (Tec-Dara) in Patients With Relapsed Refractory Multiple Myeloma: Analysis of MajesTEC-3 Based on Cytogenetic and Functional Risk$

MM - 349

Teclistamab Plus Daratumumab (Tec-Dara) in Patients With Relapsed Refractory Multiple Myeloma: Analysis of MajesTEC-3 Based on Cytogenetic and Functional Risk

Kaci Ernst

Poster Presenter: Kaci Ernst

Video

MM - 351

Extraosseous Plasmacytoma: Real-World Outcomes of a Rare Plasma Cell Neoplasm using the SEER Database

Vidushi Reddy Gillela

Poster Presenter: Vidushi Reddy Gillela

Thumbnail for Prognostic Factors for Castleman Disease Include Tumor Diameter, Lymphocyte Count, Estimated Glomerular Filtration Rate, and Low-Density Lipoprotein Cholesterol: A Retrospective Cohort Study

MM - 369

Prognostic Factors for Castleman Disease Include Tumor Diameter, Lymphocyte Count, Estimated Glomerular Filtration Rate, and Low-Density Lipoprotein Cholesterol: A Retrospective Cohort Study

Kezhi Huang

Poster Presenter: Kezhi Huang

MM - 374

Severe Opportunistic Infection Signals Associated With BCMA- and GPRC5D-Directed Bispecific Antibodies in Multiple Myeloma

Alexander Den Boef

Poster Presenter: Alexander Den Boef